Astral Codex Ten Podcast cover image

Response To Alexandros Contra Me On Ivermectin

Astral Codex Ten Podcast

00:00

Is It Possible to Re-Analyze a Study in Brazil?

Ivan Meckton does worst in studies of intermediate clinical endpoints, link in post, hospitalisation, ICU admission, recovery time. Stronger-Loydy's hypothesis tries to provide it. But I erred on my earlier post by holding it up as THE explanation for a large and heterogeneous group of studies which were mostly looking at endpoints other than mortality. It does best in studies of viral clearance rate and mortality. Viral clearance rate is a weak pre-clinical end point - not that interesting unless it affects later clinical outcomes. Many drugs change secondary endpoints but fail to change the things we care about. A parent positive results of Ivan Meckton here require

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app